Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy [2]

Infection

Volumn 34, Issue 6, 2006, Pages 357-360

  Carvalhal, A S ^a,d   Belmonte Abreu, P ^a   Correa, J ^b   Goldani, L Z ^b   Rourke, S B ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; MALE; MOTOR DYSFUNCTION; NERVOUSNESS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISUAL MEMORY;

ADULT; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; COGNITION DISORDERS; DEVELOPING COUNTRIES; FEMALE; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MOTOR SKILLS DISORDERS; NEUROPSYCHOLOGICAL TESTS; RNA, VIRAL;

EID: 33845692373     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-006-6610-6     Document Type: Letter

References (21)

1. Robertson KR, Robertson WT, Sutapa F, Watson D, Fiscus S, Harp A, Hall C: Highly Active Antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36: 562-566.
2. Dougherty RH, Skolasky RL, McArthur JC: Progression of HIV-associated dementia treated with HAART. AIDS Reader 2002; 12: 69-74.
3. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2000; 13: 1249-1253.
4. Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC: Changes in CSF and Plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60: 1388-1390.
5. Hecht F: Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998; 10: 57-59.
6. Butters N, Grant I, Haxby J, Judd LL, Martin A, McClelland J, Pequegnat W, Schacter D, Stover E: Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol 1990; 12: 963-978.
7. Ceitlin L, Santos B, Parisoto L: Elaboration of word lists in portuguese with emotional content and their influence on memory function in normal sybjects. Int J Methods Psychiatr Res 1995; 5: 195-203.
8. Spreen O, Strauss E: A compendium of neuropsychological tests: administration, normas, and commentary. Oxford University Press, New York, 1991.
9. Wechsler D: Wechsler memory scale-revised manual. Psychological Corporation, San Antonio, 1987.
10. Lezak M: Neupsychological assessment. Oxford University Press, New York, 1995.
11. Golden C; Stroop Test de colores y palabras. TEA Ediciones, Madrid, 1994.
12. Batchelor J, Harvey A, Bryant R: Stroop color word test as a measure of attentional deficit following mild head injury. Clin Neuropsychol 1995; 9: 180-186.
13. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on therapy for HIV dementia and related cognitive disorders. Clinical confirmation of neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology 1996; 47: 1247-1253.
14. Tashima K, Caliendo A, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP: Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-864.
15. Albright A, Erickson-Viitanen S, O'Connor M, Frank I, Rayner M, Gonzalez-Scarano F: Efavirenz is a potent nucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Res Hum Retroviruses 2000; 16: 1527-1537.
16. Ferrando S, Rabkin J, Van Gorp W, Lin S-H, McElhiney M: Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003; 15: 208-214.
17. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL: Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573-1578.
18. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K: Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993; 33: 343-349.
19. Starace F, Bartoli L, Aloisi M, Antinori A, Narciso P, Ippolito G, Ravasio L, Moioli MC, Vangi D, Gennero L, Coronado OV, Giacometti A, Nappa S, Perulli ML, Montesarchio V, La Gala A, Ricci F, Cristiano L, De Marco M, Izzo C, Pezzotti P, D'Arminio Monforte A: Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeurolCONA study. Acta Psychiatr Scand 2002; 106: 20-26.
20. Neuenburg J, Brodt H, Herndier B, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W: HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-177.
21. Polis M, Suzman D, Voder C, Shen JM, Mican JM, Dewar RL, Metcalf JA, Falloon J, Davey RT Jr, Kovacs JA, Feinberg MB, Masur H, Piscitelli SC: Suppression ocerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS 2003; 17: 1167-1172.